Minhai COVID-19 vaccine
Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | KCONVAC (Chinese: 可维克; pinyin: Kěwéikè) |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
.svg.png.webp){kind=small} COVID-19 portal |
Clinical trials
In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1]
Later, KCONVAC started phase II trials with 1,000 participants in China.[2]
In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]
Authorizations
On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]
References
- "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.
{{cite journal}}: CS1 maint: url-status (link) - "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.
{{cite journal}}: CS1 maint: url-status (link) - "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 20 April 2021. Retrieved 22 April 2021.
{{cite journal}}: CS1 maint: url-status (link) - "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.
{{cite journal}}: CS1 maint: url-status (link) - "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 12 August 2021. Retrieved 12 August 2021.
{{cite journal}}: CS1 maint: url-status (link) - Reuters Staff (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.